Naslov
Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis

Autori
Kiltz, U ; van der Heijde, D ; Boonen, A ; Akkoc, N ; Bautista-Molano, W ; Burgos-Vargas, R ; Wei, JC ; Chiowchanwisawakit, P ; Dougados, M ; Duruoz, MT ; Elzorkany, BK ; Gaydukova, I ; Gensler, LS ; Gilio, M ; Grazio, Simeon ; Gu, J ; Inman, RD ; Kim, TJ ; Navarro-Compan, V ; Marzo-Ortega, H ; Ozgocmen, S ; Pimentel Dos Santos, F ; Schirmer, M ; Stebbings, S ; Van den Bosch, FE ; van Tubergen, A ; Braun, J

Izvornik
Annals of the rheumatic diseases (0003-4967) 77 (2018), 9; 1311-1317

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
ankylosing spondylitis ; outcomes research ; spondyloarthritis

Sažetak
Objectives: To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease- specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). Methods: A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24weeks using standardised response mean (SRM). Results: Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath AnkylosingSpondylitisFunctioning Index: 0.71). Internal consistency was high (Cronbach's α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM=-0.44 for non-steroidal anti-inflammatory drugs, -0.69 for conventional synthetic disease-modifying antirheumatic drug and -0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values ≤5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values ≥12.0 are specific to represent poor health as opposed to moderate health. Conclusions: The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA